Overview

SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
0
Participant gender:
All
Summary
The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Salvat
Criteria
Inclusion Criteria:

- Patients suffering from OAB for at least 6 months prior to inclusion

Exclusion Criteria:

- Pregnant and breastfeeding women

- Any medical condition or need for co-medication which interferes with the drug under
investigation (SVT-40776) or the comparator (tolterodine)